Based on our Pharmacor Atrial Fibrillation advisory service, Decision Resources is offering an exclusive analyst call entitled Atrial Fibrillation: Will Emerging Agents With Novel Mechanisms of Action Overcome the Limitations of Current Treatments?
Date & Time
Recorded live on Tuesday, August 16, 2011
This 15-minute analyst call, presented by Decision Resources Analyst Matthew Killeen, Ph.D., will answer the following questions:
- What promising, emerging antiarrhythmic therapies are in development for atrial fibrillation and, according to interviewed experts, what are the potential key advantages and drawbacks of these agents?
- Can IV vernakalant (Cardiome/Merck’s Kynapid/Brinavess) secure approval in the United States and what are the prospects for oral vernakalant?
- What are some of the major challenges facing developers of novel antiarrhythmic drugs as they advance their products from the bench to the bedside?
This analyst call was held on August 16, 2011.
Contact us to learn how you can purchase this service and access the recorded event.
Click here to view the invite.